VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer

20260 citationsJournal Articlehybrid Open Access

Authors

Sara A. Hurvitz · University of Washington

Rachel M. Layman · The University of Texas MD Anderson Cancer Center

Giuseppe Curigliano · University of Milan

Fabrice André · Institut Gustave Roussy

Massimo Cristofanilli · Cornell University

Sung-Bae Kim · Ulsan College

J. Martinez Rodriguez

Abstract

The addition of gedatolisib to fulvestrant, with or without palbociclib, significantly reduced the risk of disease progression or death in patients with hormone receptor-positive/HER2-, <i>PIK3CA</i> WT advanced breast cancer.

Topics & Keywords

Advanced Breast Cancer Therapies PI3K/AKT/mTOR signaling in cancer Cancer-related Molecular Pathways

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

DOI: 10.1200/jco-25-02643

Field-Weighted Citation Impact: 0.00